Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (December 2023)
23 slides from Alterity Therapeutics's shareholder meeting presentation, Dec 29, 2023
Slide 1: Alterity Therapeutics EGM
For personal use only Alterity Therapeutics (NASDAQ:ATHE, ASX:ATH) David Stamler, MD EGM – 29 December 2023 CEO
Slide 2: Forward Looking Statements
For personal use only Forward Looking Statements This presentation may contain some statements that may be considered “Forward-Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward-looking statement relating to financial projections or other statements relating to the
Slide 3: Overview of Today's Presentation
Overview of Today’s Presentation • New Primate data with ATH434 For personal use only • Update on our clinical programs • Looking forward to 2024 3
Slide 4: Parkinsonian Disorders: A Significant Unmet Need
Parkinsonian Disorders: A Significant Unmet Need • Parkinsonism is a syndrome of motor symptoms that For personal use only includes slowed movement, stiffness and tremor • Parkinson’s disease most common cause • Major source of disability PARKINSON’S DISEASE PSP 4
Slide 5: Parkinsonian Disorders: A Significant Unmet Need
Parkinsonian Disorders: A Significant Unmet Need • Parkinsonism is a syndrome of motor symptoms that PARKINSONIAN DISORDERS For personal use only includes slowed movement, stiffness and tremor • Parkinson’s disease most common cause • Major source of disability MSA • Parkinsonian disorders include M
Slide 6: Increased Brain Iron in Parkinson's Disease and Related Disorders
Increased Brain Iron in Parkinson’s Disease and Related Disorders Parkinson’s disease Multiple System Atrophy For personal use only n=7 * Patients Substantia nigra (T) n=8 n=9 Cerebral cortex Healthy n = 11 n=8 * Substantia nigra (pc) n=3 n=8 * Caudate nucleus n = 13 n = 10 Cerebellum n = 24 n=8 * 0
Slide 7: Increased Brain Iron in Parkinson's Disease and Related Disorders
Increased Brain Iron in Parkinson’s Disease and Related Disorders Parkinson’s disease Multiple System Atrophy For personal use only n=7 * Patients Substantia nigra (T) n=8 n=9 Cerebral cortex Healthy n = 11 n=8 * Substantia nigra (pc) n=3 n=8 * Caudate nucleus n = 13 n = 10 Cerebellum n = 24 n=8 * 0
Slide 8: Excess Iron and Alpha-Synuclein are Strong Contributors to Disease Pathology
Excess Iron and Alpha-Synuclein are Strong Contributors to Disease Pathology For personal use only Oxidative Stress α-Synuclein: protein critical for normal function of neurons • Adverse impact of excess iron • Promotes α-synuclein aggregation/clumping Neuroinflammation Iron Imbalance • Root cause o
Slide 9: Approach: Address Underlying Pathology of Disease
Approach: Address Underlying Pathology of Disease For personal use only Reduce α‐synuclein Redistribute excess iron aggregation Rescue neuronal in the Central Nervous System and function Oxidative stress Potential Disease Modifying Therapy 9
Slide 10: ATH434: Disease Modifying Drug Candidate
ATH434: Disease Modifying Drug Candidate • ATH434 redistributes excess iron and reduces For personal use only α‐synuclein clumping in brain • Oral agent (tablet) for ease of use • Readily absorbed, shown to reach site of action in man • Potential to treat various Parkinsonian disorders • Orphan Drug
Slide 11: Primate Study Validates ATH434 Clinical Approach
Primate Study Validates ATH434 Clinical Approach Promising New Data For personal use only • Well established model of Parkinson’s, primate closer to humans • ATH434 treatment improved motor skills and general behavior in monkeys with experimentally induced Parkinson’s disease • Favorable impact on P
Slide 12: Monkey Parkinson's Disease Study
Monkey Parkinson’s Disease Study For personal use only Disease Onset Baseline Daily oral doses Train, habituate Placebo vs ATH434 3 mg/kg vs ATH434 10 mg/kg Week 0 4 8 12 12 - 14 Motor Assessment Motor Assessment Motor Assessment Measure Brain Iron Source: Bradbury, et al, “Effects of ATH434, a Clin
Slide 13: ATH434 Improved Motor and Behavior Scores
ATH434 Improved Motor and Behavior Scores Improvement Associated with Reduced Iron For personal use only General Motor General Behavior 8 24 6 18 Score** Score * 4 12 2 6 0 better better 0 Baseline Week 12 Baseline Week 12 * Fine motor skills, eating, eyeblink Placebo (veh) ** Appetite, response to
Slide 14: ATH434 Improved Motor and Behavior Scores
ATH434 Improved Motor and Behavior Scores Improvement Associated with Reduced Iron For personal use only General Motor General Behavior 8 24 6 18 Score** Score * 4 12 2 6 0 better better 0 Baseline Week 12 Baseline Week 12 * Fine motor skills, eating, eyeblink Placebo (veh) ** Appetite, response to
Slide 15: ATH434 Improved Motor and Behavior Scores
ATH434 Improved Motor and Behavior Scores Improvement Associated with Reduced Iron For personal use only General Motor General Behavior 8 24 6 18 Score** Score * 4 12 2 Lowest Lowest 6 Iron Iron Levels Levels 0 better better 0 Baseline Week 12 Baseline Week 12 * Fine motor skills, eating, eyeblink P
Slide 16: Accumulated Data Supports ATH434 Efficacy
Accumulated Data Supports ATH434 Efficacy Neurons/ Clinical Target Disease Model Brain Iron α-Synuclein Author Connectivity Observations For personal use only Improved motor Parkinson’s disease Mouse MPTP Finkelstein performance Improved motor Parkinson’s disease Mouse A53T Finkelstein p
Slide 17: Clinical Development Progress in Multiple System Atrophy
For personal use only Clinical Development Progress in Multiple System Atrophy 17
Slide 18: Promising Portfolio in Neurodegenerative Diseases
Promising Portfolio in Neurodegenerative Diseases For personal use only ASSET PHASE PARTNER PRE- NATURAL PARTNER / PROGRAM INDICATION DISCOVERY PHASE 1 PHASE 2 CLINICAL HISTORY COLLABORATOR Multiple System Atrophy ATH434-201 Enrollment Complete Early Stage Multiple System Atrophy ATH434-202 Advanced
Slide 19: Clinical Development in MSA
Clinical Development in MSA Study ATH434-201 – Phase 2 ATH434-202 – Phase 2 bioMUSE – Natural History For personal use only Randomized, double-blind, Design Single arm, open-label Observational placebo controlled Efficacy and safety of ATH434 Efficacy and safety of ATH434 Design and de-risk Phase 2
Slide 20: Significant Commercial Opportunity in Treating Multiple System Atrophy
Significant Commercial Opportunity in Treating Multiple System Atrophy For personal use only Substantial Unmet Need Strong Intent to Prescribe Severely debilitating illnesses Motivated by efficacy of treating with no current treatments are the underlying disease and not ripe for new entrants targeti
Slide 21: Key Milestones
Key Milestones For personal use only Enrollment Complete ATH434-201 Phase 2 Trial Data with ATH434 in Monkey Model Study Complete of Parkinson’s ATH434-201 Disease Phase 2 Trial bioMUSE Data Preliminary Data from ATH434-202 Open Label Biomarker Trial Oct Nov Dec Jan Feb Mar Apr May Jun July Aug Sep
Slide 22: Poised for Progress in 2024
Poised for Progress in 2024 • New primate data validates our clinical strategy For personal use only • Achieved all clinical and corporate milestones in 2023 • ATH434: Novel drug candidate for various parkinsonian disorders • First indication: Multiple System Atrophy (MSA) • ATH434-201 (early-stage
Slide 23: Alterity
off. Alterity For personal use only
Alterity Therapeutics — Shareholder Meeting (December 2023) on 6ix